Atara Biotherapeutics

Our Clinical Studies

Swapna: Small intestine
transplant, PTLD Advocate

Clinical studies are necessary to investigate new therapies but they can’t move forward without patient participation which is essential. If you are interested in one of our clinical studies, please speak with your doctor or if you are a healthcare professional, please contact us for more information.

Clinical Studies in
B-Cell Mediated Diseases

NHL Study

Phase 1 study to evaluate the safety and preliminary efficacy of ATA3219 in subjects with relapsed/refractory B-cell non-Hodgkin’s lymphoma
REQUEST INFO clinicaltrials.gov

SLE Study

Phase 1 study to evaluate the safety and preliminary efficacy of ATA3219 in subjects with systemic lupus erythematosus
REQUEST INFO clinicaltrials.gov

Clinical Studies in EBV-associated Diseases

ALLELE Study

Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant participants with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy
REQUEST INFO clinicaltrials.gov

EBVision (205) Study

A study to evaluate tabelecleucel in participants with Epstein-Barr virus-associated diseases*
REQUEST INFO clinicaltrials.gov

*EBV-associated diseases being studied include: EBV+ lymphoproliferative disease (LPD) in the setting of primary immunodeficiency (PID) (PID LPD); EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency (AID) (AID LPD); EBV+ posttransplant lymphoproliferative disorder involving the central nervous system (CNS PTLD); EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not appropriate, including CD20 negative disease; EBV+ sarcomas, including leiomyosarcoma (LMS).

The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.

EBV=Epstein-Barr virus; EBV+=EBV positive; HLA=human leukocyte antigens; PTLD=post-transplant lymphoproliferative disease.

NEXT: OUR MISSION